Evidence map›Paper›PMID 40528195›Full record

ArticleJournal of translational medicine2025

Interleukin-1β mediates a tumor-supporting environment prompted by IGF1 in triple-negative breast cancer (TNBC).

Domenica Scordamaglia, Marianna Talia, Francesca Cirillo, Azzurra Zicarelli, Adelina Assunta Mondino, Salvatore De Rosis, Marika Di Dio, Francesca Silvestri, Chiara Meliti, Anna Maria Miglietta and 5 more

Abstract read
In one paragraph

Article in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Domenica Scordamaglia *Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, 87036, Rende, Italy.
Marianna Talia *Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, 87036, Rende, Italy.
Francesca CirilloDepartment of Medicine and Surgery, University of Enna "Kore", 94100, Enna, Italy.
Azzurra ZicarelliDepartment of Medicine and Surgery, University of Enna "Kore", 94100, Enna, Italy.
Adelina Assunta MondinoDepartment of Pharmacy, Health and Nutritional Sciences, University of Calabria, 87036, Rende, Italy.
Salvatore De RosisDepartment of Pharmacy, Health and Nutritional Sciences, University of Calabria, 87036, Rende, Italy.
Marika Di DioDepartment of Pharmacy, Health and Nutritional Sciences, University of Calabria, 87036, Rende, Italy.
Francesca SilvestriDepartment of Pharmacy, Health and Nutritional Sciences, University of Calabria, 87036, Rende, Italy.
Chiara MelitiDepartment of Pharmacy, Health and Nutritional Sciences, University of Calabria, 87036, Rende, Italy.
Anna Maria MigliettaBreast and General Surgery Unit, Annunziata Hospital Cosenza, 87100, Cosenza, Italy.
Carlo CapalboDepartment of Pharmacy, Health and Nutritional Sciences, University of Calabria, 87036, Rende, Italy.
Ernestina Marianna De FrancescoDepartment of Medicine and Surgery, University of Enna "Kore", 94100, Enna, Italy.
Antonino BelfioreEndocrinology, Department of Clinical and Experimental Medicine, University of Catania, Garibaldi-Nesima Hospital, 95122, Catania, Italy.
Marcello MaggioliniDepartment of Pharmacy, Health and Nutritional Sciences, University of Calabria, 87036, Rende, Italy. marcello.maggiolini@unical.it.
Rosamaria LappanoDepartment of Pharmacy, Health and Nutritional Sciences, University of Calabria, 87036, Rende, Italy. rosamaria.lappano@unical.it.

Funding

Fondazione AIRC per la ricerca sul cancro ETS 23369Fondazione AIRC per la ricerca sul cancro ETS 27386Fondazione AIRC per la ricerca sul cancro ETS Start-Up Grant 21651Ministero dell'Università e della Ricerca 2022Y79PT4Ministero dell'Università e della Ricerca PNRR P2022MALRPMinistero dell'Università e della Ricerca Prin 2022 202282CMEA
6 · The paper itself

Abstract

backgroundThe intricate mechanisms that associate obesity with triple-negative breast cancer (TNBC) remain to be disclosed. Considering that obesity is linked with an increased bioavailability of the insulin-like growth factor 1 (IGF1), we evaluated whether IGF1 triggers aggressive features in TNBC cells and the molecular paths involved.

methodsGene expression and Chromatin Immunoprecipitation experiments, ELISA, immunoblotting, immunoprecipitation and immunofluorescence assays, combined with two-dimensional and three-dimensional in vitro model-based studies, were used to investigate the molecular mechanisms through which IGF1 may promote proliferative and motile responses in TNBC cells and reprogram normal fibroblasts into cancer-associated fibroblasts (CAFs)-like cells. The translational relevance of the results obtained was supported by bioinformatics analyses leveraging data from extensive TNBC patient databases.

resultsWe found that the cytokine interleukin-1β (IL-1β) mediates certain IGF1 actions within the tumor microenvironment, hence facilitating the TNBC landscape. Mechanistically, we assessed that the IGF1/IGF1 receptor (IGFIR) axis induces the collagen VI-dependent activation of discoidin domain receptor 1 (DDR1) and the subsequent increase of the G protein estrogen receptor (GPER), toward IL-1β regulation and secretion. Consequently, IL-1β promoted both the autocrine stimulation of TNBC cells and the differentiation of normal fibroblasts into cancer-associated fibroblasts (CAFs)-like cells, which in turn achieved a proliferative profile and enhanced the motility of TNBC cells.

conclusionsIL-1β may be considered as a therapeutic target in more comprehensive approaches in obese TNBC patients exhibiting high IGF-1 bioavailability.

Indexed as

Insulin-Like Growth Factor IInterleukin-1betaTriple Negative Breast NeoplasmsTumor MicroenvironmentCancer-Associated FibroblastsCell Line, TumorCell MovementCell ProliferationFemaleGene Expression Regulation, NeoplasticHumansReceptor, IGF Type 1Receptors, EstrogenSignal TransductionIGF1 protein, humanInsulin-Like Growth Factor IInterleukin-1betaReceptor, IGF Type 1Receptors, EstrogenCancer associated fibroblasts (CAFs)Discoidin domain receptor 1 (DDR1)G protein estrogen receptor (GPER)Insulin-like growth factor 1 (IGF1)Interleukin 1β (IL1β)Triple-negative breast cancer (TNBC)

Identifiers

PMID40528195
PMCPMC12172323

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.